Professor Alan Burnett, Head of Haematology Department of Medical Genetics, Cardiff, Wales, talks to ecancer.TV about the nucleoside analogue, clofarabine, in acute myeloid leukaemia (AML). He outlines the interesting history, the early promise of the drug in older patients and the original clinical studies in three different patient groups. Professor Burnett then discusses the best combination with clofarabine, including ara-C. He goes on to note other compounds being studied in AML, such as agents that target FLT3 mutations in relapsed disease, eg, AC220, and outlines the pros and cons.
Other aspects touched on that are yet to be tested in the randomised setting include the benefit of prognostic mutations. Also, Professor Burnett discusses the techniques being developed for minimal residual disease assessment and the potential value of these.
Finally, Professor Burnett updates viewers on advances in the management of elderly patients with AML.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).